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A B S T R A C T
Pneumonia is one of the potential complications of general anaesthesia in horses. Anaesthesia is known
to increase neutrophils in bronchoalveolar lavage ﬂuid (BALF) of horses after lateral recumbency, but
studies after dorsal recumbency are lacking. Our primary aim was to determine when lung inﬂammation
reaches its maximum and how rapidly BALF cytology returns to baseline after anaesthesia in dorsal
recumbency. A secondary aim was to investigate the possible effect of vatinoxan, a novel drug, on the
BALF cytology results.
Six healthy experimental horses were enrolled in this observational crossover study. The horses were
subject to repeated BALF and blood sampling for 7 days after general anaesthesia with two treatment
protocols, and without anaesthesia (control). During the two treatments, the horses received either
medetomidine-vatinoxan or medetomidine-placebo as premedication, and anaesthesia was induced
with ketamine-midazolam and maintained with isoﬂurane for 1 h in dorsal recumbency. The differences
in BALF and blood variables between the two anaesthesia protocols and control were analysed with
repeated measures analysis of variance models.
In this study, anaesthesia in dorsal recumbency resulted in no clinically relevant changes in airway
cytology that could be differentiated from the effect of repeated BALF sampling. No differences in BALF
matrix metalloproteinase gelatinolytic activity could be detected between the two treatments or the
control series. Marked increase in serum amyloid A was detected in some animals. Vatinoxan as
premedication did not consistently affect lung cytology or blood inﬂammatory markers after anaesthesia.
© 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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The complication rate in equine general anaesthesia is
considered high compared with that in several other species
(Johnston et al., 2002; Brodbelt, 2009). Postanaesthetic pneumonia
has been described as one of the potential complications of general
anaesthesia in horses (Grubb and Muir, 2005; Monticelli and
Adami, 2019). In humans, pre-existing pulmonary disease,
advanced age of the patient, atelectasis during anaesthesia, and
aspiration of gastric contents have been considered as predispos-
ing factors for postanaesthetic pneumonia (Ephgrave et al., 1993;
Fujita and Sakurai, 1995; Kozlow et al., 2003). In horses, general
anaesthesia causes atelectasis and gas-exchange impairment in
the lungs (Nyman et al., 1990). Furthermore, horses are often
subjected to mechanical ventilation during general anaesthesia,* Corresponding author. Tel.; +3582941911.
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species (Dos Santos and Slutsky, 2000). However, the effects of
general anaesthesia on inﬂammatory responses in the lungs and on
systemic inﬂammatory markers, such as serum amyloid A (SAA)
are poorly understood in horses.
In healthy horses anaesthetised in lateral recumbency, neu-
trophils increase in the epithelial lining ﬂuid in the dependent lung
(Ito et al., 2003), but it is not known what level and duration of
lower-airway neutrophilia can be expected after anaesthesia in
dorsal recumbency. This information is warranted in clinical
practice, when early differentiation of bacterial pneumonia from
other causes of post-anaesthetic fever is crucial.
In horses, α2-adrenoceptor agonists such as medetomidine
are used as pre-anaesthetic agents and in constant-rate
infusions in general anaesthesia. Vatinoxan (previously MK-467
and L-659,066) is an α2-adrenoceptor antagonist that poorly
penetrates the blood-brain barrier and therefore selectively targets
peripherally located α2-adrenoceptors (Clineschmidt et al., 1988).
Combining vatinoxan with an α2-adrenoceptor agonist improvedcle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2018) and horses (Pakkanen et al., 2015), in addition to its
cardiovascular effects. In sheep, vatinoxan reduced dexmedeto-
midine-induced bronchoconstriction and pulmonary oedema
(Adam et al., 2018). However, in horses, the mechanism leading
to improvement in PaO2 is currently unknown. Vatinoxan also
alleviates the reduction in gastrointestinal motility induced by α2-
adrenoceptor agonists in horses (Vainionpää et al., 2013; de Vries
et al., 2016; Tapio et al., 2018), which may improve oesophageal
tonus and reduce the risk of aspiration of gastric ﬂuids during
general anaesthesia and the recovery period.
The primary aim of this study was to investigate the effect of
general anaesthesia in dorsal recumbency on equine lower airway
cytology and selected inﬂammatory biomarkers in clinically healthy
horses, and to evaluate how rapidly the cytology recovers after
anaesthesia. A secondary aim was to assess the possible effect of
vatinoxan on airway cytology. We hypothesised that anaesthesia
would induce a transient increase in the percentage of neutrophils in
bronchoalveolarlavage ﬂuid(BALF) and thatvatinoxanwould reduce
atelectasis or potential micro-aspiration during general anaesthesia
resulting in reduced lung inﬂammation after anaesthesia.
Materials and methods
Study design
In this observational crossover study, three series of BALF sampling were
performed in each horse. Two of the series were performed after two different
anaesthetic protocols (treatments) and one as a control series without anaesthesia.
Each horse was anaesthetised twice for 1 h in dorsal recumbency using
medetomidine-vatinoxan (MED + V) or medetomidine-placebo (MED) as premed-
ication. The order of the anaesthetic protocols was randomised with a two-
treatment paired crossover Latin-square design. A minimum of 2-week washout
period was used between both treatments and control BALF sampling series.
Animals
Six experimental horses (age range 5–19 years, median 10 years), three mares
and three geldings, four Standardbreds and two Warmbloods, median body mass of
521 kg (range 476–571 kg) were used. The horses were considered clinically healthy
based on clinical examination, blood sample results (haematology and serum
biochemistry) and the lack of clinical respiratory signs. During the study period,
physical examination of the horses was performed daily, and possible signs of
cough, nasal discharge or other abnormal signs were recorded. The study was
approved by the Committee for Experimental Animals of Southern Finland
(Approval number ESAVI/4789/04.10.07/2014; Approval date 19 June 2014).
Anaesthetic protocol
The horses were not fed for 12 h prior to each anaesthesia. A venous catheter
was placed into the left jugular vein (Intraﬂon, Kruuse). Ten min before induction,
all horses received 7 mg/kg medetomidine (Dorbene, Vetcare) intravenously (IV)
either with 140 mg/kg vatinoxan (Vetcare; MED + V) or with an equal volume of
saline placebo (MED). Premedications were mixed in the same syringe. Anaesthesia
was induced with 2.2 mg/kg ketamine (Ketaminol, Intervet) and 0.06 mg/kg
midazolam (Midazolam Hameln, Hameln Pharmaceuticals) mixed in the same
syringe and administered IV. After intubation, the horses were positioned in dorsal
recumbency and connected to the breathing system (Tafonius, Hallowell).
Anaesthesia was maintained with 3.5 mg kg1 h1 medetomidine infusion and
isoﬂurane (Isoba, Schering-Plough) in 100% oxygen. The lungs were mechanically
ventilated (7 times per minute, 1.2 L/100 kg), resulting in positive inspiratory
pressures of 16–26 mmHg). Dobutamine was infused when needed to maintain the
mean arterial blood pressure above 70 mmHg. The horses recovered in left lateral
recumbency.
Bronchoscopy and airway sampling
Bronchoscopy was performed and BALF samples collected 1 h, 20 h, 2 days, 3
days and 7 days after anaesthesia as described previously (Couëtil and Hawkins,
2013) with a 220 cm-long, 11 mm-diameter video endoscope (Pentax Medical).
For bronchoalveolar lavage (BAL), 240 mL of sterile 0.9% saline at room
temperature per lung was used. To decrease coughing, 60 mL of 1% lidocaine
(Lidocain, Orion Pharma) was injected onto the carina and mainstem bronchi.
Syringes with the retrieved BALF samples were immediately placed on ice and
submitted for laboratory analysis within 30 min of collection. The samples wereconsidered adequate when they contained a foamy surfactant layer. No samples
had to be discarded due to inadequate quality. Observational bronchoscopy
ﬁndings before sampling were recorded. Similar series of BALF samples
(control) were obtained from the same horses without anaesthesia a minimum
of 2 weeks before the ﬁrst anaesthesia (3/6 horses) or 2 weeks after the second
anaesthesia (3/6 horses). Cytological analysis of the BALF samples was
performed, as described previously (Rossi et al., 2017). Reference values for
the BALF cell types were obtained from the American College of Veterinary
Internal Medicine revised consensus statement (Couëtil et al., 2016) and
literature (Couëtil and Hawkins, 2013), with a neutrophil count of >5%
considered abnormal. Matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9)
combined gelatinolytic activity was measured in BALF from both lungs using the
method described by Rossi et al. (2017).
Blood samples
An arterial blood sample was anaerobically collected for blood-gas analysis at
the end of anaesthesia (Pico 50, Radiometer Medical). The sample was placed in ice
water and analysed (ABL800 Flex; Radiometer Medical) within 10 min, and the
values were temperature-corrected to concurrent measurements of rectal
temperature. Ethylenediaminetetraacetic acid (EDTA) plasma and serum samples
were collected 24 h before each anaesthesia (Pre-ane) and 20 h, 2 days, 3 days and 7
days after anaesthesia from the jugular vein, and analysed within 1 h after
collection. The SAA concentration was measured with an immunoturbidometric
assay (Eiken SAA LZ, Eiken Chemical). Serum activity of aspartate aminotransferase
(AST) and creatine kinase (CK) were measured with an automatic clinical chemistry
analyser (Konelab 30i, Thermo Fischer Scientiﬁc). The total leukocyte count was
determined (ADVIA 2120i Haematology System, Siemens Healthcare Diagnostics)
and the ﬁbrinogen concentration was measured with the heat precipitation
method.
Statistical analysis
Considering BALF neutrophil percentage between treatments as the primary
outcome and with an expected mean of the paired differences of 16 and an expected
standard deviation of 8, a sample size of ﬁve horses was required to achieve a power
of 80% and a level of signiﬁcance of 5% (two sided).
The differences between the three treatments (control, MED and MED + V) in
the change in the BALF variables from the baseline were analysed with repeated
measures analysis of variance models. The models included treatment, time point,
period and the interaction between the treatment and time point as ﬁxed terms and
the horse as the random factor. The baseline was deﬁned as the ﬁrst sample of the
control series within each horse. The sequence effect was excluded from the
models, because the randomisation was conducted only for the MED and MED + V
treatments. The sides of the lung (right/left) were analysed separately.
The blood samples were drawn during the MED and MED + V treatments only;
therefore, the corresponding variables were analysed assuming a 2  2–crossover
design. The changes from baseline (within the period) were analysed with repeated
measures analysis of covariance models. The models included baseline covariate,
treatment, time point, sequence, period and treatment*time point as ﬁxed terms.
The horse effect (within the sequence) together with the interaction terms of
treatment*horse (sequence) and time point*horse (sequence) were used as random
terms in the models.
Spearman’s rank correlation coefﬁcients were calculated for SAA and neutrophil
percentage or gelatinolytic activity in each lung. Due to the exploratory nature and
small number of horses, no multiplicity adjustment methods were applied.
Statistical analyses were performed using SAS System for Windows, version 9.3
(SAS Institute) and IBM SPSS statistical package version 22 (IBM). The differences
were considered statistically signiﬁcant at P < 0.05.
Results
The horses remained in good health during the study period,
and none developed clinical signs of pneumonia (e.g. fever). All
recoveries from anaesthesia were uneventful. However, one horse
presented with cough on a single day during the washout period
after the ﬁrst anaesthesia (MED), and two horses presented with
cough during the BALF sampling period after the MED + V
anaesthesia. In all horses, bronchoscopy revealed serous ﬂuid
accumulation (from mild to marked) in the trachea at the level of
the thoracic inlet, 1 h after both anaesthetic episodes. Fluid
accumulation was no longer detected at later time points. The
results of the cytological analysis of BALF during the three
treatments are presented in Table 1 for the right lung and in
Table 2 for the left lung. There were no consistent differences
regarding cytology or the total gelatinolytic activity of MMP-2
Table 1
Mean  standard deviation (SD) and range (min–max) bronchoalveolar lavage ﬂuid (BALF) cytology and gelatin zymography results of the right lung at 1 h, 20 h, 2 days, 3 days
and 7 days after general anaesthesia in dorsal recumbency with medetomidine-placebo (MED) and medetomidine-vatinoxan (MED + V) premedication and control.
1 h 20 h 2 days 3 days 7 days
Neutrophils (%) Control 3.2  1.2 10.9  8.5 10.4  10.7 8.0  4.8 3.9  2.4
(1.4–4.7) (3.0–22.7) (2.7–31.7) (1.4–13.0) (1.4–7.4)
MED 4.4  3.6 9.3  7.2 14.1  13.8 13.4  6.0 2.9  1.7
(0.4–9.4) (1.4–18.0) (1.0–41.0) (5.7–20.0) (1.0–5.0)
MED + V 4.1  3.2 4.9  2.7 5.2  4.7c 8.0  3.8 3.8  3.6
(1.0–9.7) (1.7–8.0) (0.4–12.4) (2.4–12.7) (0.0–10.4)
Eosinophils (%) Control 0.2  0.3 1.5  2.9 0.3  0.3 0.4  0.3 0.3  0.3
(0.0–0.7) (0.0–7.4) (0.0–0.7) (0.0–0.7) (0.0–0.7)
MED 0.1  0.3 0.5  0.8a 0.1  0.3 0.4  0.4 0.3  0.3
(0.0–0.7) (0.0–2.0) (0.0–0.7) (0.0–1.0) (0.0–0.7)
MED + V 0.1  0.2 0.2  0.3 0.3  0.4 0.3  0.3 0.0  0.0
(0.0–0.4) (0.0–0.7) (0.0–1.0) (0.0–0.7) (0.0–0.4)
Mast cells (%) Control 1.7  0.6 1.3  0.3 0.9  0.8 1.5  1.1 1.6  1.2
(0.7–2.4) (1.0–1.7) (0.0–2.0) (0.4–3.4) (0.0–3.4)
MED 2.3  1.7 1.8  0.5 2.0  2.0 1.5  1.1 2.3  1.5
(0.7–5.4) (1.4–2.7) (0.0–5.0) (0.4–3.7) (0.7–4.0)
MED + V 2.6  2.1 2.1  1.3 2.7  3.4b 1.7  1.1 1.2  0.6
(0.4–5.7) (0.7–4.0) (0.0–9.0) (0.7–3.7) (0.4–2.0)
Lymphocytes (%) Control 56.6  5.4 58.7  15.5 58.3  16.3 62.1  11.0 52.3  7.0
(49.0–62.7) (33.4–73.0) (40.0–76.4) (48.4–79.0) (44.7–63.0)
MED 59.1  6.6 66.1  8.7 55.6  9.3 60.7  9.8 55.3  10.2
(49.7–68.0) (55.7–78.0) (44.7–68.4) (42.0–68.7) (41.7–70.7)
MED + V 56.8  10.9 64.0  7.0 65.5  12.3 68.7  9.9 58.2  10.1
(39.7–72.4) (55.7–72.4) (48.7–79.4) (52.4–80.4) (43.0–69.0)
Macrophages (%) Control 38.6  6.0 28.0  5.8 30.3  14.4 28.2  8.6 42.0  9.1
(32.0–47.4) (21.4–37.7) (16.4–54.4) (16.4–41.0) (27.4–51.0)
MED 33.3  8.9 24.0  6.1 28.0  12.2 24.1  9.7 39.4  8.7
(23.4–46.4) (16.0–31.0) (13.7–43.7) (13.0–38.7) (27.7–53.0)
MED + V 36.6  14.1 28.8  7.9 26.2  12.3 21.6  10.2 36.7  10.9
(18.4–58.7) (20.4–40.7) (12.0–46.7) (14.4–39.4) (20.4–52.7)
Total gelatinolytic activity (arbitrary units) Control 5.6  4.0 26.1  31.3 10.9  10.7 13.8  15.4 6.8  9.2
(2.0–12.2) (3.7–88.0) (1.7–29.5) (3.4–44.6) (1.8–25.5)
MED 6.8  4.8 8.0  7.2 19.3  32.2 14.8  12.0 3.7  2.1
(2.0–12.9) (2.7–21.7) (1.7–84.8) (4.0–33.2) (1.9–7.7)
MED + V 10.9  10.4 7.1  4.0 4.6  3.1 6.9  3.9 6.0  8.6
(1.9–27.0) (1.2–10.5) (2.5–10.7) (3.1–12.9) (1.2–23.3)
a P < 0.05 between control and MED for change from common baseline.
b P < 0.05 between control and MED + V for change from common baseline.
c P < 0.05 between MED and MED + V for change from common baseline.
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or control.
After MED anaesthesia, the BALF neutrophil percentage
increased in both lungs above the reference range in all horses
and peaked in the right lung at 20 h in 2/6 horses, at 2 days in 1/6
horses and at 3 days in 3/6 horses. In the left lung, the neutrophil
percentage peaked at 20 h in 1/6 horses, at 2 days in 3/6 horses
and at 3 days in 2/6 horses. At 7 days after anaesthesia, all horses
showed BALF neutrophil percentages within the reference range
in the right lung and all horses except one (no. 2) showed normal
BALF neutrophil percentages in the left lung. The overall increase
in neutrophils from the baseline was signiﬁcant in the right lung
(P = 0.014).
Following the MED + V anaesthesia, the BALF neutrophil
percentage increased in both lungs above the reference range in
all horses except one and peaked in the right lung at 2 days in 1/5
horses and at 3 days in 4/5 horses. In the left lung, the neutrophil
percentage peaked at 20 h in 2/5 horses, at 2 days in 1/5 horses, at 3
days in 1/5 horses and at 7 days in 1/5 horses. While one horse (no.
2) showed peak values at 7 days, all other horses showed normal
cytology in both lungs 7 days after anaesthesia.
In the control series, the BALF neutrophil percentage increased
above the reference range in the right lung in all horses and peaked
at 20 h in 3/6 horses, at 2 days in 2/6 horses and at 3 days in 1/6
horses. In the left lung, the neutrophil percentage increased above
the reference range in 3/6 horses, and peaked at 20 h in 1/3 horses,
at 2 days in 1/3 horses and at 3 days in 1/3 horses. At day 7 in thecontrol series, 2/6 horses showed BALF neutrophil percentage
slightly above reference range in the right lung (horses no. 2, 4). All
horses had normal neutrophil percentage in the left lung 7 days
after anaesthesia.
The SAA concentration showed marked interindividual varia-
tion (Table 3), peaked in most horses at 2 days and returned to the
reference range at 7 days in all horses except one (no. 2), which also
showed the highest peak (923.9 mg/L). Two horses showed no
increase in SAA above the reference limit of 20 mg/L (Jacobsen
et al., 2006) after the MED anaesthesia. Overall, no statistically
signiﬁcant changes from baseline values or within any of the
individual time points with either treatment were detected. The
SAA concentration correlated slightly with the BALF neutrophil
percentage in the right lung (r = 0.324, P = 0.011) and left lung
(r = 0.400, P = 0.001) and also with the BALF total gelatinolytic
activity of MMP-2 and -9 in the right lung (r = 0.338, P = 0.008) and
left lung (r = 0.487, P < 0.001). At the end of anaesthesia, the PaO2
was 250  112 mmHg (range 133–386; MED) and 260  118 mmHg
(range 109–420; MED + V), and there was no signiﬁcant difference
between the two anaesthetic protocols. Serum muscle enzyme
activities (AST and CK) were within the reference range at all time
points in all horses.
Discussion
In this study, we primarily investigated the effect of general
anaesthesia in dorsal recumbency on equine lower airway cytology
Table 3
Mean  standard deviation (SD) and range (min–max) total blood leukocyte count, ﬁbrinogen and serum amyloid A (SAA) concentration 24 h before the general anaesthesia
(Pre-ane) and 20 h, 2 days, 3 days and 7 days after general anaesthesia in dorsal recumbency with medetomidine-placebo (MED) and medetomidine-vatinoxan (MED + V)
premedication.
Pre-ane 20 h 2 days 3 days 7 days
Leukocyte count (109/L) 7.0  1.7 MED 9.4  2.0a 8.3  1.3 8.3  1.8 7.1  1.3
(5.7–9.3) (6.8–11.9) (6.0–9.7) (6.3–11.3) (5.0–9.4)
6.7  1.2 MED + V 10.4  2.0 a,b 8.9  1.4a 7.6  1.2 6.7  1.5
(4.9–8.0) (8.3–13.3) (7.2–10.6) (6.5–9.7) (5.3–8.8)
Fibrinogen (g/L) 3.4  0.5 MED 3.9  0.4 4.1  0.5a 4.2  0.6a 3.8  0.7
(2.8–4.1) (3.4–4.4) (3.3–4.6) (3.5–4.8) (3.0–4.7)
3.2  0.4 MED + V 3.8  0.4a 3.8  0.5a 4.0  0.4a 3.8  0.4
(2.6–3.6) (3.1–4.2) (3.4–4.7) (3.7–4.7) (3.5–4.5)
SAA (mg/L) 0.3  0.7 MED 83.4  117.8 212.1  369.5 191.1  332.9 27.4  63.0
(0.0–1.7) (0.5–246.8) (0.7–923.9) (0.5–817.8) (0.3–155.8)
0.5  0.7 MED + V 131.9  82.8 207.1  175.0a 134.3  121.3 4.0  8.0
(0.0–1.7) (24.3–221.7) (20.3–476.0) (1.4–259.7) (0.0–20.2)
a P < 0.05 for change from Pre-ane within treatment.
b P < 0.05 between MED and MED + V.
Table 2
Mean  standard deviation (SD) and range (min–max) bronchoalveolar lavage ﬂuid (BALF) cytology and gelatin zymography results of the left lung at 1 h, 20 h, 2 days, 3 days
and 7 days after general anaesthesia in dorsal recumbency with medetomidine-placebo (MED) and medetomidine-vatinoxan (MED + V) premedication and control.
1 h 20 h 2 days 3 days 7 days
Neutrophils (%) Control 4.4  3.1 4.5  4.0 5.4  5.4 3.1  3.8 2.0  1.8
(1.0–9.0) (1.0–9.4) (1.4–16.0) (0.7–10.7) (0.0–4.0)
MED 5.5  3.9 10.5  11.0 10.2  9.1 11.8  12.2a 4.2  3.9
(1.0–11.7) (2.4–29.4) (1.4–24.4) (2.4–35.4) (1.7–12.0)
MED + V 4.0  3.0 7.4  6.2 10.0  15.1 4.0  1.9c 3.4  3.8
(2.0–10.0) (1.7–15.4) (2.0–40.7) (1.0–6.0) (0.7–10.7)
Eosinophils (%) Control 0.3  0.2 0.5  0.7 0.4  0.4 0.4  0.3 0.0  0.0
(0.0–0.4) (0.0–1.7) (0.0–1.0) (0.0–0.7) (0.0–0.0)
MED 0.4  0.4 0.2  0.3a 0.1  0.3a 0.1  0.2a 0.2  0.2
(0.0–0.7) (0.0–0.7) (0.0–0.7) (0.0–0.4) (0.0–0.4)
MED + V 0.4  0.4 0.5  0.6c 0.2  0.3 0.1  0.2b 0.3  0.2
(0.0–1.0) (0.0–1.4) (0.0–0.7) (0.0–0.4) (0.0–0.4)
Mast cells (%) Control 2.0  0.8 2.2  1.1 1.8  0.8 3.5  2.3 1.7  0.9
(1.0–3.0) (1.4–4.4) (0.4–2.7) (1.4–7.0) (0.7–2.7)
MED 3.0  1.9 3.0  1.1 1.7  1.0 2.4  1.7 1.8  1.0
(1.0–5.7) (1.4–4.4) (1.0–3.4) (1.0–5.4) (0.7–3.0)
MED + V 1.6  0.8c 1.6  1.5c 1.7  0.3 2.8  1.6 2.1  0.9
(1.0–2.7) (0.0–4.4) (1.4–2.0) (1.0–5.4) (1.4–3.7)
Lymphocytes (%) Control 54.7  7.3 54.7  8.9 63.7  7.3 55.1  11.8 56.8  8.5
(44.0–65.0) (45.4–68.0) (51.4–71.4) (42.7–71.7) (45.4–68.4)
MED 62.3  5.5 55.3  10.4 58.0  2.7 58.8  9.5 57.9  12.1
(58.0–71.7) (36.0–63.4) (54.7–61.4) (46.7–73.0) (36.0–69.7)
MED + V 63.4  9.1b 64.3  10.4b,c 55.0  15.4 63.3  4.1b 52.3  12.0d
(45.7–70.7) (49.7–75.7) (32.0–68.0) (59.7–70.4) (38.7–68.7)
Macrophages (%) Control 38.8  5.3 39.4  9.4 28.9  10.4 38.1  12.4 39.7  7.3
(32.4–43.7) (28.4–50.7) (15.4–44.7) (21.4–52.7) (29.7–49.4)
MED 28.7  6.3a 31.2  9.1a 30.1  9.8 27.1  10.1a 36.1  12.8
(22.4–37.7) (17.0–43.4) (13.4–40.0) (12.5–38.4) (23.7–58.7)
MED + V 30.7  10.1b 26.0  4.9b 33.0  15.4 29.8  3.7b 42.0  10.9d
(19.7–49.5) (20.4–33.4) (17.0–62.0) (22.7–33.4) (29.4–56.0)
Total gelatinolytic activity (arbitrary units) Control 3.0  1.4 8.3  7.4 7.8  6.9 4.2  1.9 4.0  3.5
(1.5–5.6) (3.7–23.3) (2.6–21.1) (1.3–6.1) (1.3–11.0)
MED 7.2  5.0 8.3  8.2 10.3  11.2 10.8  10.5 5.1  5.7
(0.9–12.8) (0.0–22.5) (0.9–28.3) (0.0–25.7) (1.5–16.4)
MED + V 5.6  4.1 10.1  9.7 6.9  5.6 7.8  8.3 5.0  5.6
(2.2–13.3) (1.7–24.1) (1.5–17.2) (2.2–24.0) (1.5–16.2)
a P < 0.05 between control and MED for change from common baseline.
b P < 0.05 between control and MED + V for change from common baseline.
c P < 0.05 between MED and MED + V for change from common baseline.
d P < 0.05 between 1 h and 7 days within treatment.
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neutrophilia in the lungs since no consistent, clinically relevant
differences were detected in BALF cytology between the control
series and general anaesthesia. However, neutrophils increased in
the BALF after both anaesthetic episodes, as well as in the control
series, and returned to baseline within 7 days in most horses. These
ﬁndings suggest that the increase in neutrophils was likely due to
the effect of repeated BALF sampling and not anaesthesia. This is incontrast to previous reports in which repeated sampling did not
increase the neutrophil counts (Clark et al., 1995; Tee et al., 2012).
On the other hand, Sweeney et al. (1994) demonstrated that BALF
sampling caused a local inﬁltration of neutrophils to the sampling
site that persisted at least 48 h, although it did not cause a diffuse
inﬂammation when the airway adjacent to the ﬁrst BAL site was
sampled. Therefore, the increase in the relative neutrophil counts
in this study observed in the control, MED and MED + V sampling
H. Rossi et al. / The Veterinary Journal 251 (2019) 105352 5series may have been due to repeated sampling of the same part of the
distal airway, which could have possibly been avoided by sampling the
adjacent bronchus of the previously sampled airway. However, in
humans, neutrophil recruitment has also been observed in adjacent
bronchi after BALF sampling (Von Essen et al., 1991). In the present
study, lidocaine was used to reduce coughing during BALF sampling in
both treatments and the control group. The use of lidocaine is unlikely
to affect the quantity or quality of BALF cytology results in horses
(Westermann et al., 2005), and therefore should not have affected the
conclusions in this study.
Ito et al. (2003) demonstrated that during an anesthetic episode
of 2 h in lateral recumbency in healthy horses, neutrophils increase in
the BALF of the dependent lung and return to normal within 7 days.
The increase was interpreted to be mostly due to compression
atelectasis of the dependent lung, since no changes were detected in
the other lung (Ito et al., 2003). In our study, the horses were placed in
dorsal recumbency, which causes atelectasis to both dorsal lung ﬁelds
(Nyman et al.,1990). This could explain why no consistent or clinically
relevant differences could be found between right and left lung
cytology. On the other hand, general anaesthesia itself did not cause a
signiﬁcant increase in neutrophils in comparison to the control series.
This discrepancy between our results and the study by Ito et al. (2003)
might be caused by a shorter anaesthetic time (1 h) in our experiment,
and consequently, a shorter duration of atelectasis. Moreover, Ito et al.
(2003) did not use controls to study the possible effect of repeated
BALF sampling which might have contributed tothe BALF neutrophilia
detected in that study.
Our results showed large individual variation in BALF cytology
in healthy horses, which did not develop signs of pneumonia after
general anaesthesia. However, some horses presented with
occasional coughing during the BALF sampling series. In the
absence of other clinical signs or signiﬁcant increases in ﬁbrinogen
or body temperature, this was considered to be associated with the
local irritation of airways as a consequence of repeated sampling
and not pneumonia. However, neither tracheal ﬂuid microbiology
nor lung ultrasonography or radiography were performed to
conﬁrm the absence of pneumonia. Pneumonia or pleuropneumo-
nia in horses often causes changes in the airway cytology, although
Rossier et al. (1991) reported that only 10/22 horses with
pneumonia or pleuropneumonia showed abnormal BALF cytology,
including an increase in absolute or relative number of neutrophils.
This highlights the fact that it is not possible to diagnose
pneumonia based solely on BALF cytology.
In all horses, a mild to marked serous ﬂuid accumulation was
detected in the trachea but not in the mainstem bronchi shortly
after anaesthesia, and this disappeared within 1 day. The origin of
the ﬂuid remains unclear; however, it may have originated from
the upper airways and trachea due to local mucous membrane
irritation and congestion, because oedema ﬂuid originating from
the alveoli would probably have been frothy (Kollias-Baker et al.,
1993; Ball and Trim, 1996; Kaartinen et al., 2010).
As a secondary aim, we investigated the possible effect of
vatinoxan on airway inﬂammation and cytology, but we did not
ﬁnd signiﬁcant differences between the two anaesthesia protocols.
We hypothesised that vatinoxan would reduce atelectasis or
potential micro-aspiration during general anaesthesia resulting in
reduced lung inﬂammation after anaesthesia. Although macro-
aspiration of gastric contents has been reported as a peri-
anaesthetic complication in horses with colic (Monticelli and
Adami, 2019), there is currently no evidence whether micro-
aspiration of gastric contents can occur during general anaesthesia
in horses similarly to people (Ephgrave et al., 1993). In our study,
the horses did not develop marked lung inﬂammation related to
anaesthesia, and therefore macro- or micro-aspiration seems
unlikely in these horses, which might explain why no effect of
vatinoxan on the airway cytology was observed. Moreover, in thisstudy, vatinoxan did not affect the PaO2 at the end of either
anaesthetic protocol, when atelectasis was expected to peak.
Pakkanen et al. (2015) found that PaO2 was higher at 40 min of
anaesthesia in horses anaesthetised with vatinoxan as part of the
premedication protocol, but the difference was no longer found at
60 min, which is in agreement with our results. Therefore, it is
possible that vatinoxan affects lung function earlier in the
anaesthetic episode, although in our study, no difference was
detected in lung inﬂammation after either anaesthetic protocol.
SAA is a major acute-phase protein and may increase in several
conditions, including various inﬂammatory and infectious diseases
and surgical trauma in horses (Pepys et al.,1989). In our study, some
of the horses showed marked elevations in SAA after both
anaesthetic episodes, in contrast to others presenting almost no
or only mild elevation. Furthermore, a signiﬁcant but clinically
irrelevant increase was also detected in plasma ﬁbrinogen concen-
tration in some horses. SAA was weakly correlated with both
neutrophil percentage and total gelatinolytic activity of MMP-2 and
-9 in BALF. SAA was also measured during the control series in four
horses where it remained in the reference range. Unfortunately, due
to technical problems, SAA was not measured during the control
series in two horses, which would have allowed statistical
comparison with the concentration after anaesthesia. Nevertheless,
marked interindividual variation in the SAA response to general
anaesthesia was observed. Further studies are warranted to explain
the wide variation detected and to establish reference ranges for SAA
in horses after anaesthesia, which could aid in the early detection of
post-anaesthetic pneumonia or other infections.
Several limitations of the study need to bepointed out. The number
of horses was calculated to be sufﬁcient to detect clinically signiﬁcant
changes in cytology. However, less variation was expected in the
results, and therefore the number of animals may have been too small
to identify clinically relevant changes. One of the six horses (no. 2)
showed marked neutrophilia both in the control series and after both
anaesthetic episodes. This horse also showedthe most substantial SAA
increase and failure of normalising SAA at 7 days. The marked
neutrophilia and increase in SAA detected in this horse may suggest
the presence of an underlying subclinical problem, such as mild
asthma orother inﬂammatory oreven infectious disease, although the
physical examination and haematology screening before anaesthesia
were normal. Moreover, other extrapulmonary causes for an increase
in SAA after anaesthesia are possible, including myopathy due to
hypotension or rough recovery or any other inﬂammation or infection.
However, in this study, myopathy due to hypotension seems an
unlikely reason for the increase in SAA since the muscle enzyme
activities remained within the reference ranges, and rough recoveries
were not detected.
The control series BALF collection was performed before both
anaesthetic episodes in half of the horses and after a 2-week
washout period following the second anaesthesia in the other
half. Theoretically, the anaesthetic episodes could have caused a
subclinical inﬂammation in the lungs of these three horses that
may have affected the control series results. However, the
neutrophils were within the reference range in all of these
horses in the ﬁrst sample of the control series. The ﬁrst sample
of the control series was used as a baseline for statistical
comparison in all treatments. The horses were also used for
another study in which respiratory and cardiovascular param-
eters were measured during anaesthesia (Tapio et al., 2019), and
therefore, we were unable to obtain baseline BALF samples prior
to general anaesthesia for the purpose of not affecting lung
function during anaesthesia. The baseline may have changed
over time; however, the total study period including both
anaesthetic episodes and all three BALF sampling series was
short. In our patient population, typical duration of anaesthesia
for common procedures (e.g. castration) is approximately 1 h,
6 H. Rossi et al. / The Veterinary Journal 251 (2019) 105352and therefore this duration was set as the length of the
anaesthesia. However, longer duration of anaesthesia might
have led to different results regarding BALF and blood variables.
Conclusions
In this study, anaesthesia in dorsal recumbency caused no
clinically signiﬁcant changes in airway cytology that could be
differentiated from the effect of repeated BALF sampling. Inclusion
of vatinoxan in the premedication did not result in clinically
relevant effects on lung cytology after anaesthesia.
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